BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) acquired Zacharon Pharmaceuticals, Inc. from Avalon Ventures and other shareholders for approximately $140 million in cash on January 4, 2013. As part of consideration, an amount of $1.7 million was held in escrow. As per the deal, BioMarin Pharmaceutical may make potential additional payments of $134 million if certain clinical, development and sales milestones. BioMarin acquired $0.56 million cash of Zacharon. William Blair & Company, L.L.C. acted as the financial advisor for Zacharon Pharmaceuticals. Jennifer Fonner DiNucci, Marya Postner, Renee Deming, Natasha Leskovsek, Lois Voelz, Buff Miller, Dan Espinoza, Robin Bennett, Eric Chow, Laura McDaniels and Michael Baker of Cooley LLP acted as legal advisor for BioMarin. Carl Sanchez, Scott Oross, Elizabeth Razzano, Laura McGurty and Kevin Reyes of Paul Hastings LLP acted as legal advisors for Zacharon.

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) completed the acquisition of Zacharon Pharmaceuticals, Inc. from Avalon Ventures and other shareholders on January 4, 2013.